Literature DB >> 18317866

Rimonabant for overweight and "metabolic syndrome": the attempt to supersize disease and risk by pharmaceutical marketing.

Rita Banzi1, Lorenzo Moja, Ivan Moschetti, Alessandro Liberati, Gian Franco Gensini, Roberto Gusinu, Andrea A Conti.   

Abstract

Entities:  

Year:  2008        PMID： 18317866     DOI： 10.1007/s11739-008-0139-x

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  18 in total

1.  Selling sickness: the pharmaceutical industry and disease mongering.

Authors:  Ray Moynihan; Iona Heath; David Henry
Journal:  BMJ       Date:  2002-04-13

2.  The uncertainty principle and industry-sponsored research.

Authors:  B Djulbegovic; M Lacevic; A Cantor; K K Fields; C L Bennett; J R Adams; N M Kuderer; G H Lyman
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

Review 3.  Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications.

Authors:  Hans Melander; Jane Ahlqvist-Rastad; Gertie Meijer; Björn Beermann
Journal:  BMJ       Date:  2003-05-31

4.  Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

Authors:  Jean-Pierre Després; Alain Golay; Lars Sjöström
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

5.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

Review 6.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

7.  Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Authors:  André J Scheen; Nick Finer; Priscilla Hollander; Michael D Jensen; Luc F Van Gaal
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

Review 8.  Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.

Authors:  Robin Christensen; Pernelle Kruse Kristensen; Else Marie Bartels; Henning Bliddal; Arne Astrup
Journal:  Lancet       Date:  2007-11-17       Impact factor: 79.321

9.  Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

Authors:  Diana Rucker; Raj Padwal; Stephanie K Li; Cintia Curioni; David C W Lau
Journal:  BMJ       Date:  2007-11-15

10.  Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others.

Authors:  Lisa Bero; Fieke Oostvogel; Peter Bacchetti; Kirby Lee
Journal:  PLoS Med       Date:  2007-06       Impact factor: 11.069
View more
  1 in total

1.  Obesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorship.

Authors:  John M McPartland
Journal:  PLoS One       Date:  2009-03-31       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.